This year, PT Bundamedik Tbk (BMHS) targets revenue growth of 15-20%.

The company expects to achieve performance growth through business development after conducting an Initial Public Offering (IPO) on the Indonesia Stock Exchange (IDX).

"In terms of overall revenue, we expect growth to occur annually by 15% to 20% for the BMHS group," said Director of Bundamedik Nurhadi Yudiyantho in Jakarta, Tuesday (6/7).

In 2021, the company will focus on supporting government programs through the Ministry of Health, namely restoring the health of the Indonesian people amid the COVID-19 pandemic.

"The BMHS Group through Laboratory Diagnostics has carried out quite a number of screening examinations in the community, then in our mother's hospital group we carried out treatment for patients with COVID-19," explained Nurhadi.

Bundamedik also supports the government's massive COVID-19 vaccination program and hopes that vac